DMD and Anxiety: We thus demonstrate that anxiety, fear-related behaviors and fear conditioning performance constitute a set of relevant outcome measures in the evaluation of novel therapies aimed at alleviating CNS comorbidities associated with loss of dystrophin isoforms in the brain.